ImageneBio, Inc. (NASDAQ:IMA – Get Free Report) was the target of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 61,349 shares, a growth of 86.7% from the September 30th total of 32,852 shares. Currently, 0.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 14,638 shares, the days-to-cover ratio is currently 4.2 days.
Wall Street Analyst Weigh In
IMA has been the topic of a number of research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of ImageneBio in a research note on Friday, September 25th. HC Wainwright initiated coverage on shares of ImageneBio in a report on Friday, August 21st. They set a “buy” rating and a $28.00 target price for the company. One research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, ImageneBio currently has an average rating of “Reduce” and a consensus target price of $28.00.
Get Our Latest Stock Report on IMA
Hedge Funds Weigh In On ImageneBio
A number of institutional investors have recently made changes to their positions in IMA. Blue Owl Capital Holdings LP acquired a new stake in shares of ImageneBio during the second quarter valued at $5,414,000. Cable Car Capital LP purchased a new stake in ImageneBio during the 2nd quarter worth about $4,611,000. Trails Edge Capital Partners LP acquired a new position in ImageneBio in the 2nd quarter valued at about $1,663,824. BlackRock Inc. acquired a new position in ImageneBio in the 2nd quarter valued at about $797,000. Finally, Stonepine Capital Management LLC acquired a new position in ImageneBio in the 2nd quarter valued at about $539,044,000. 75.00% of the stock is owned by institutional investors and hedge funds.
ImageneBio Price Performance
Shares of ImageneBio stock opened at $4.10 on Friday. ImageneBio has a 1 year low of $3.88 and a 1 year high of $8.84. The company has a market capitalization of $46.53 million, a P/E ratio of -0.90 and a beta of 0.74. The business has a 50 day moving average price of $4.67 and a 200 day moving average price of $5.64.
ImageneBio (NASDAQ:IMA – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.27. As a group, research analysts expect that ImageneBio will post -3.23 EPS for the current fiscal year.
About ImageneBio
ImageneBio, Inc is a biotechnology company focused on advancing precision oncology through blood-based molecular testing and data analysis. The company develops technologies designed to help identify and monitor cancer-related genomic signals using liquid biopsy samples.
Its platform is intended to support the detection and tracking of tumor biomarkers, potentially helping clinicians assess treatment response, identify disease progression, and guide more personalized cancer-care decisions.
Further Reading
- Five stocks we like better than ImageneBio
- L3Harris Stock Took a Beating—Is a 20% Rebound Next?
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
Receive News & Ratings for ImageneBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImageneBio and related companies with MarketBeat.com's FREE daily email newsletter.
